Insight Molecular Diagnostics Inc. Q3 2025 Earnings Recap

IMDX Q3 2025 November 11, 2025

Get alerts when IMDX reports next quarter

Insight Molecular Diagnostics demonstrated significant progress in their Q3 2025 performance, highlighting advancements in their GraftAssure DX assay and preparing for an anticipated strong market introduction in 2026.

Earnings Per Share Miss

$-0.34 vs $-0.24 est.

-41.7% surprise

Revenue Miss

260000 vs 285000 est.

-8.8% surprise

Market Reaction

1-Day +10.66%

5-Day +8.82%

30-Day -22.94%

See IMDX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Successfully optimized GraftAssure DX’s test workflow from two steps to one, enhancing turnaround time and ease of use for transplant centers.
Positive feedback and data from pilot studies at multiple sites indicate high confidence in assay performance ahead of the upcoming FDA submission.
A growing interest in in-house testing from transplant centers drives demand, supported by a new registry program aimed at collecting real-world data on the assay’s performance.
Statistical equivalence demonstrated against legacy tests reinforces GraftAssure’s competitive position, enabling easier transitions for clinicians.
First reports using the anticipated Centimeters score are expected in 2026, with early access for registry participants, fostering early adoption.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit IMDX on AllInvestView.